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Alzheimer’s disease (AD); (2) relationships between other patient characteristics and these clinical
end points; and (3) whether effects of the predictors change across time.
Methods: The authors conducted a multicenter, natural history study that included three university-
based AD centers in the United States. A total of 201 patients diagnosed with probable ADwith mod-
ified Mini-Mental State Examination (MMSE) scores  30 at study entry were monitored annually
for 6 years. Discrete-time hazard analyses were used to examine relationships between ChEI and
memantine use during the previous 6 months reported at each assessment, and time to cognitive
(MMSE score 10) and functional (Blessed Dementia Rating Scale score 10) end points and mor-
tality. Analyses controlled for clinical characteristics, including baseline cognition, function, and co-
morbid conditions, and presence of extrapyramidal signs and psychiatric symptoms at each
assessment interval. Demographic characteristics included baseline age, sex, education, and living
arrangement at each assessment interval.
Results: ChEI use was associated with delayed time in reaching the functional end point and death.
Memantine use was associated with delayed time to death. Different patient characteristics were as-
sociated with different clinical end points.
Conclusions: Results suggest long-term beneficial effects of ChEI and memantine use on patient
outcomes. As for all observational cohort studies, observed relationships should not be interpreted
as causal effects.
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Since their introduction, cholinesterase inhibitors
(ChEIs) and, later, the N-methyl-D aspartate receptor antag-thor. Tel.:1718-584-9000 ext 6146; Fax:1718-741-
rolyn.zhu@mssm.edu
nt matter  2013 The Alzheimer’s Association. All rights r
16/j.jalz.2012.09.015onist (memantine) have been shown in short-term clinical
trials and longer term open-label extension studies to stabi-
lize or reduce the rate of decline in measures of cognitive
function, activities of daily living, and behavior in some pa-
tients with Alzheimer’s disease (AD) [1–11]. Most rigorous
evidence of whether the effects of ChEIs and memantine
are sustained over longer periods of time would come
from long-duration, prospective, placebo-controlled trials.eserved.
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also are ethical concerns associated with exposing patients
to placebo in trials of long duration because ChEIs and
memantine have become the standard of care for patients
with AD. In the absence of these trials, observational studies
based on practice-based populations may be one of the only
ways to evaluate the effects of these medications [12].
Several studies have assessed the effects of ChEIs and/or
memantine treatment in real-world clinic settings [13–22].
Results from these studies have been mixed. In one of the
first observational studies on the effects of ChEI on patient
outcomes, Doody and colleagues [13] found slowed decline
in cognitive function after a year in patients treated with
ChEIs compared with untreated patients. Comparing pa-
tients treated with ChEI or ChEI1 memantine combination
therapy with an untreated earlier cohort of patients, Atri and
associates [17] also reported slower decline in cognition and
function in the treated group. Persistent treatment has been
shown to be associated with slowed decline in cognition
and function, but effects may be lost if treatment is disrupted
[3,18]. On the other hand, in another study comparing
a cohort of patients treated with ChEIs with an earlier
cohort of untreated patients, Lopez and coworkers [14,19]
reported no association between ChEI use and time to
cognitive and functional decline or to death, but significant
delays in nursing home admission.
In an earlier study using a large, multicenter cohort of
patients with probable AD who were monitored prospec-
tively up to 6 years from early-disease stages, we reported
that patterns of ChEI and memantine use changed substan-
tially over time and were consistent with practice guidelines
of initiating ChEIs in mild to moderate AD, and adding
memantine in moderate to severe AD [23]. In the current
study, we take advantage of the availability of important
clinical characteristics (eg, comorbid conditions, psychiatric
symptoms) that were not controlled for before, the long
follow-up period, and more current data, and further investi-
gated the following questions: Are ChEIs or memantine use
associated with length of time to reach cognitive and func-
tional outcomes and death? Are these associations stable
over time?2. Methods
2.1. Sample
Data are drawn from the Predictors 2 cohort, consisting
of patients recruited from Columbia University Medical
Center, Johns Hopkins School of Medicine, and Massachu-
setts General Hospital. The study was approved by each
local institutional review board. The inclusion/exclusion
criteria have been described fully elsewhere [24–26].
Briefly, subjects met Diagnostic and Statistical Manual of
Mental Disorders, edition 3, revised, criteria for primary
degenerative dementia of the Alzheimer type and National
Institute of Neurological Diseases and Stroke/Alzheimer’sDisease and Related Disorders Association criteria for
probable AD. Enrollment required a modified Mini-Mental
State Examination score  30, equivalent to approximately
 16 on the Folstein MMSE [27,28]. Clinical diagnosis of
AD has been confirmed in 93% of those with postmortem
evaluation [26].
Study recruitment began in 1997, when widespread use of
ChEIs began in the United States, and is ongoing. After the
baseline assessment, patients were monitored annually.
Thosewhomissed a particular visit could respond at a subse-
quent visit. The cohort used in the current analysis included
201 patients who were monitored for up to 6 years and pro-
vided data for 785 visits. Of these 201 patients, 13 had
6 years of follow-up visits, 27 had 5 years of follow-up visits,
37 had 4 years of follow-up visits, 34 had 3 years of follow-
up visits, and 41 had 2 years of follow-up visits. One hundred
twenty-three patients (61%) did not miss any visits, 15 pa-
tients (7%) missed one visit, 19 patients (9%) missed two
visits, 22 patients (10%) missed three visits, and the rest of
the patients missed four or more visits. Median follow-up
for the cohort was 4 years (mean, 3.5 years; SD, 2.0).2.2. Measures2.2.1. Clinical end points
We usedMMSE scores to assess patients’ cognitive status
and constructed a dichotomous variable indicating an
MMSE score  10 at each visit. We used Blessed Dementia
Rating Scale (BDRS) Parts I and II (Instrumental and Basic
Activities of Daily Living) to assess patients’ functional
status and constructed a dichotomous variable indicating a
BDRS score 10 at each visit. We chose these cutoff points
because similar scores have been used as outcomes in many
studies. Exploratory analyses of neighboring end points (ie,
MMSE score  8 and BDRS score  8) did not change
estimation results substantively. Patient deaths were most
often reported by family members when we attempted to
complete follow-up visits. For patients who could not be
contacted, information on death was obtained through the
National Death Index.
2.2.2. Main independent variables: ChEI and memantine
use
All prescription and over-the-counter medication use dur-
ing the previous 6 months were reported at each visit by the
patient and informant on a medication acquisition form.
Information reported included name of medication, number
of days taking the medication, dosage, and number of pills
per day. Because ChEIs have been shown to have similar ef-
ficacy despite slightly different pharmacological properties,
we combined all ChEIs into one group.
Because of the consistency of medication use reported in
this sample, we constructed dichotomous variables indicat-
ing ChEI and memantine use during the 6 months prior to
each assessment as our main independent variables instead
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ber of days of use or medication dosages.
2.2.3. Other substantive control variables
To isolate the effects of ChEI and memantine use, we
controlled for the following time-variant variables in the
analysis. Columbia University Scale for Psychopathology
in AD, a semistructured interview administered by physi-
cians or trained research technicians, was used to measure
psychotic symptoms [29]. A modified Unified Parkinson’s
Disease Rating Scale was used to measure presence of extra-
pyramidal signs [30,31]. Information on patients’ living
arrangements at each assessment was dichotomized as
living at home or in a long-term care facility. The follow-
ing time-invariant characteristics were included in the
analysis: baseline cognition, function, number of comorbid-
ities, baseline age, sex, education, and study site [26,32].
Because ChEIs and memantine were approved by the U.S.
Food and Drug Administration for treatment of AD at
different times, year of study entry was included to control
for availability of medications on the market and any
differences that could be related to different entry times
into the study. Because most of the sample population was
white (n 5 188, 94%), ethnicity was not included in the
models.2.3. Analysis
We used discrete-time hazard models to examine the re-
lationships between ChEI and memantine use, and time to
cognitive and functional end points and mortality. We used
binary, time-specific event indicators for BDRS scores,
MMSE scores, and death to reflect the first year a patient
reached a clinical end point. Right censoring occurred
when a patient did not reach a clinical end point by their
most recent assessment. Such patients would have a zero
on the time-specific event indicator for all assessment inter-
vals up to the most recent assessment. Observations with
missing outcomes were dropped from the analysis.
The estimated discrete-time hazard is the conditional
probability that patients reach a clinical end point in an as-
sessment interval, given that they did not reach the end point
in an earlier interval. Although multiple observations from
each patient may be correlated in longitudinal data, this
conditional probability can be treated as if it came from a
distinct, independent observation, and therefore it is not
necessary to account for clustering effects within the indi-
vidual [33]. For each outcome, we first estimated a set of
models that included only time effects (year 5 0, 1,
2,.5). This set of models describes for the entire sample
the hazard profile for each clinical end point. If the estimated
coefficients are approximately the same, the risk of reaching
a clinical end point is unrelated to time and the hazard func-
tion is flat. If the estimated coefficient increases over time,
the risk of reaching a clinical end point increases and the
hazard function increases over time. We tested the constanthazard assumption using a likelihood ratio test based on
model deviance statistics.
Next, we examined bivariate relationships between each
potential substantive covariate (eg, ChEI use) and the
clinical end points after controlling for time effects. These
main effects models contain the underlying proportionality
assumption that each covariate has the same effect on the
outcome in every time period. We tested the proportionality
assumption of each covariate using deviance statistics
obtained from the unconstrained model that included the
main effect of the covariate and an interaction term of the
covariate and time in the constrained main effects model.
If the unconstrained covariate model did not fit better than
the main effects model, the covariate did not violate the
proportionality assumption and only main effects for that
covariate were included in subsequent analyses. If the un-
constrained covariate model fit better than the main effects
model, both the covariate and its interaction with time
were included in subsequent analyses [34].
Last, we estimated a full, multivariate model that in-
cluded (1) all six binary time-effects indicators, (2) main ef-
fects for covariates that did not violate the proportionality
assumption, and (3) main effects and interaction with time
effects for covariates that violated the proportionality as-
sumption. To account for possible clustering (eg, within
sites), robust standard errors were reported. The results of
this full model allowed interpretation for each individual co-
variate effect on our clinical end points after adjusting for all
other covariates.3. Results
3.1. Baseline characteristics
At baseline, patients’ average age was 76 years (SD, 8.1
years), 123 were female (61%), and 176 (88%) lived at home
(Table 1). Patients were highly educated, with an average
of 14 years of schooling (SD, 3.1 years). Average MMSE
score was 22.0 (SD, 3.4) and average BDRS score was 3.6
(SD, 2.1). Sixty-eight patients had psychotic symptoms
(34%) and 29 had extrapyramidal signs (16%). Almost
half the patients (n 5 96, 48.4%) reported no comorbid
conditions, a third (n5 67, 34.1%) reported one, and the re-
maining 38 patients (19%) reported two or more comorbid
conditions.
Table 2 presents data on the number patients who were
available for observation at each assessment interval, and
the number and proportion of those who were taking ChEIs
or memantine. Because only patients with mild AD were in-
cluded at study entry, four fifths of the 201 patients (n5 161)
reported using ChEIs at baseline and only 2% (n 5 4) re-
ported using memantine, all of whom used it in combination
with ChEIs. By year 6, the proportion of patients who re-
ported using ChEIs decreased slightly to 74.4%, the propor-
tion of patients who reported using memantine increased to
48.8%, and the proportion of patients who reported not
Table 1
Patient characteristics at baseline (n 5 201)
Variables Mean (SD) Range
Age, y 76.3 (8.0) 49–95
Female, % 61.2




Living in a nursing home, % 12.4
Folstein Mini-Mental State Examination
score
21.9 (3.4) 12–30
Modified Mini-Mental State Examination
score
37.2 (6.5) 14–52
Blessed Dementia Rating Scale score 3.6 (2.1) 0–10.5
Presence of psychiatric symptoms, % 33.8
Presence of extrapyramidal signs, % 15.9












Abbreviation: SD, standard deviation.
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steady. Overall, 182 patients (91%) reported taking ChEIs
at some point during the study and 19 patients (9.5%)
were never treated with ChEIs. Eighty-one patients
(40.2%) reported taking memantine at some point during
the study 120 patients (59.7%) were never treated with mem-
antine. Patients who were treated with ChEIs at some point
were monitored for an average of 3.6 years (SD, 2.0 years)
compared with 2.1 years (SD, 1.7 years) for those whoTable 2
Proportion of patients at each visit who reported taking cholinesterase
inhibitors or memantine
Number of patients at
each visit
Year
0 1 2 3 4 5 6
Total 201 159 127 98 93 66 43
Taking ChEI
No. of patients 161 131 99 81 70 48 32
Proportion of patients 80.1 82.4 78.0 82.7 75.3 72.7 74.4
Taking memantine
No. of patients 4 13 19 32 41 34 21
Proportion of patients 2.0 8.2 15.0 32.7 44.1 51.5 48.8
Taking both ChEI and memantine
No. of patients 4 12 16 29 33 30 19
Proportion of patients 2.0 7.5 12.6 29.6 35.5 45.5 44.2
Did not take either ChEI or memantine
No. of patients 40 27 25 14 15 14 9
Proportion of patients 19.9 17.0 19.7 14.3 16.1 21.2 20.9
Abbreviation: ChEI, cholinesterase inhibitor.were never treated with ChEIs. Patients who were treated
with memantine at some point were monitored for an aver-
age of 4.4 years (SD, 1.5 years) compared with 2.9 years
(SD, 2.0 years) for those who were never treated with
memantine.
Throughout the study period, the proportion of patients
who used specific ChEIs remained relatively stable. During
the visits in which patients reported taking ChEIs, 61.7%
reported taking donepezil; 13.6%, galantamine; and 4.8%,
rivastigmine. We examined in detail the extent and consis-
tency of using individual medications among those who
reported taking the medication. Table 3 presents baseline
data on the proportion of patients who reported taking
each medication every day (180 days during the previous
6 months) and the proportion of those who took effective
dosages for each medication. At baseline, 80.6% of patients
who were taking donepezil reported taking it every day, and
98.3% of those who were taking donepezil reported taking it
at effective doses. During the study period, in 93.3% of the
visits in which patients reported taking donepezil, they
also reported that they took it every day during the previous
6 months, and almost all reported taking it at effective doses.3.2. Unconditional hazard models
Figure 1 describes the hazard profile for the entire sample
(ie, the conditional probability that an individual would
reach a clinical end point given that the individual did not
reach the end point in an earlier interval). The hazard func-
tion for each outcome increased over time and was most pro-
nounced in patient function. Likelihood ratio tests of the
constant hazard assumption was rejected for all outcomes
(all P , .01).3.3. Multivariate discrete-time hazard analyses
Table 4 reports coefficient estimates of final multivariate
models that examined time to reach functional and cognitive
end points and mortality. Consistent with unconditional haz-
ard models, estimated hazard for each outcome increased
significantly over time. Year of study entry and site were
not associated significantly with any outcome.
After controlling for patient characteristics, ChEI use
was associated with longer time to reaching the func-
tional end point (estimated coefficient,21.282; standard er-
ror, 0.433; computed odds ratio [OR], 0.278) and mortality
(OR, 0.409). Memantine use was associated with longer
time to mortality (OR, 0.443). (Full computations of odds
ratios are available on request.) Better baseline cognition
was associated with longer time to reaching all end points.
For each point improvement in baseline MMSE score, esti-
mated odds of reaching the functional end point was 11%
lower, of reaching the cognitive end point was 21% lower,
and of dying was 13% lower. Better baseline function was
also associated with longer time to reaching the functional
end point and mortality. A 1-point worsening in baseline
Table 3
Extent and consistency of cholinesterase inhibitor and memantine use by



















Donepezil 80.6 98.3 93.3 98.9
Galantamine 83.3 61.1 88.7 73.6
Rivastigmine 77.8 77.8 81.1 78.9
Memantine 88.9 88.9 86.1 96.4
NOTE. A total of 201 patients were included at baseline and contributed
to 785 observations for the longitudinal sample throughout the study period.
*Effective dose per day for donepezil is defined to be 5 mg or 10 mg; for
galantamine, 16 to 24 mg; rivastigmine, 6 to 12 mg; and for memantine, 10
mg or 20 mg.
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the functional end point (OR, 2.0). Similarly, a 1-point wors-
ening in baseline BDRS score was associated with 36% in-
creased odds of dying (OR, 1.36). Over time, the increased
risk of reaching the functional end point and mortality
from a 1-point increase in baseline BDRS scored attenuated,
but the effect was not statistically significant. Compared
with patients without extrapyramidal signs, the odds of
reaching functional end points for those with extrapyramidal
signs was 5.6 times greater, and the odds of dying was 2.3
times higher. At each assessment interval, compared with
patients without psychiatric symptoms, the odds of reaching
functional end points for those with psychiatric symptoms























Fig. 1. Unconditional hazard model for functional, cognitive, and mortality
end points. BDRS, Blessed Dementia Rating Scale; MMSE, Mini-Mental
State Examination.3.4. Secondary sensitivity analyses: Exploring potential
association between clinical end points and irregular
ChEI use
A small subsample of patients (n 5 19) in this study re-
ported never having been treated with ChEIs. Compared
with patients who were treated with ChEIs at some point
during the study, these patients were older, more likely to
be female, had less education, had fewer years of follow-
up, and had worse baseline MMSE scores. To test whether
our results were sensitive to including patients who were
never treated, we reestimated our models using only patients
who were treated with ChEIs at some point during the study.
Results were substantively similar.
During the long course of the illness, it is likely that pa-
tients may change from treated to untreated status or vice
versa. The following treatment changes were observed in
56 patients: (1) 26 patients reported taking ChEIs at study en-
try and later discontinued; (2) 14 patients reported either tak-
ing ChEIs at study entry, discontinued at some point, and
resumed treatment later, or were not taking ChEIs at study
entry, initiated treatment at some point, and discontinued
later; and (3) 16 patients initiated and continued ChEI treat-
ment after study enrollment. Because persistent treatmenthas been associated with slowed decline in cognition and
function [3,18], we explored patterns of discontinuation as
related to reaching clinical outcomes in these 56 patients.
Bivariate distributions between medication use and clinical
end points did not show patients were taken off ChEIs
as their conditions deteriorated, although power to detect
differences was limited. Among the 81 patients who used
memantine at some point during the study, the vast
majority continued treatment once started, only six patients
discontinued after one or two assessments, one of whom
reported resuming at a later time.4. Discussion
In this study, we assessed long-term effects of ChEIs
and memantine on the natural history of AD outside the
context of controlled trials and open-label extension studies
to provide a more real-world perspective. A large cohort of
patients from early stages of AD was monitored prospec-
tively for 6 years. After controlling for important clinical
characteristics, we found ChEI use was associated with lon-
ger time to reaching functional end points and death, and
memantine use was associated with delayed mortality. As
for all observational cohort studies, common caution in
interpreting results is needed. In particular, the effects of
ChEI and memantine use observed in this study should not
be interpreted as causal effects.
A small number of studies have examined the relationship
between ChEI use and mortality. An early randomized trial
on tacrine use reported a trend toward lower mortality
among those who received higher doses (.120 mg/day) in
open-label follow up [5]. Another study reported signifi-
cantly lower 3-year mortality in tacrine users than nonusers
[20]. However, a more recent observational study comparing
patients on ChEIs with a matched, historical sample of
patients who were never exposed to ChEIs reported no asso-
ciation between ChEI use and cognitive and functional status
at 1-year of follow-up or 3-year mortality [14]. Another
Table 4
Multivariate results of discrete-time hazard models of time to reach functional and cognitive endpoints and mortality*
Variables
Functional end point (BDRS score  10) Cognitive end point (MMSE score  10) Death
Coef. (SE) Coef. (SE) Coef. (SE)
ChEI use 21.282 (0.433)y 20.379 (0.573) 20.894 (0.387)z
Memantine use 20.274 (0.388) 0.500 (0.498) 20.813 (0.450)x
Baseline MMSE score 20.095 (0.056)x 20.241 (0.074)y 20.142 (0.051)y
Baseline BDRS score 0.707 (0.196)y 0.068 (0.238) 0.307 (0.136)z
Baseline BDRS score! year 20.085 (0.055) 20.041 (0.070) 20.023 (0.037)
Presence of EPS 1.727 (0.483)y 0.836 (0.552) 0.832 (0.405)z
Presence of psychiatric symptoms 1.071 (0.772) 2.258 (0.863)y 0.758 (0.616)
Presence of psychiatric symptoms! year 20.072 (0.209) 20.526 (0.249)z 20.109 (0.170)
Baseline comorbidities 20.023 (0.376) 20.288 (0.465) 20.332 (0.287)
Baseline comorbidities! year 20.036 (0.107) 0.140 (0.139) 0.099 (0.070)
Baseline age 20.093 (0.023)y 20.116 (0.026)y 0.011 (0.019)
Female 20.533 (0.805) 0.384 (0.855) 20.152 (0.636)
Female! year 0.357 (0.217) 0.191 (0.248) 20.031 (0.173)
Education 20.066 (0.108) 0.148 (0.134) 20.074 (0.087)
Education! year 0.030 (0.030) 20.021 (0.040) 0.022 (0.025)
Living in a nursing home 0.609 (0.364)x 0.072 (0.526) 0.247 (0.375)
Abbreviations: BDRS, Blessed Dementia Rating Scale; MMSE, Mini-Mental State Examination; Coef., coefficient; SE, standard error; ChEI, cholinesterase
inhibitor; EPS, extrapyramidal signs.
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were not associated with time to death [19].
A direct comparison of our results with these studies is
difficult because of differences in study samples and meth-
odologies. Perhaps the closest study to ours is that of Lo-
pez and colleagues [19], in which 443 patients with
probable AD with at least one annual follow-up in a large
urban Alzheimer’s Disease Research Center were moni-
tored since 1997. Several differences in patient characteris-
tics between these two studies should be noted. First,
compared with the Lopez study [19], patients in our sample
were, on average, 3 years older (mean age, 76 years vs 73
years), but with higher MMSE scores at study entry (mean
MMSE score, 21.9 vs 18.2). It is possible that patients in
our sample had an earlier start in ChEI therapy, similar
to those who participate in clinical trials, and that this
may have led to the stronger mortality effects observed
in our study [35–37]. Compared with the study by Lopez
and colleagues [19], in which only 3% of subjects were
never treated with ChEIs, 10% of our patients reported
never having been treated with ChEIs. Interestingly, com-
pared with the treated patients, the never-treated group in
our study was older whereas they were significantly youn-
ger in the study by Lopez and colleagues [19].
It is also important to note methodological differences
between these studies. For example, although we included
all recruited patients in our analyses, analysis in the study
by Lopez and colleagues [19] was restricted to patients
with at least one follow-up. Differential rates of decline
or differential effectiveness of medications in patients
who did not have any follow-up data may have contributedto differences in study results. In several earlier studies,
patients who were not treated with ChEIs were derived
from historical cohorts that may have confounding effects
on the results [14,17]. It is likely that patients in the
treated, more recent cohorts were diagnosed earlier than
those in the untreated, earlier cohorts. Improvements in
medical care in more recent cohorts may have
contributed to the relative slowing of disease progression
in treated groups. These possibilities should be tested
empirically in future studies.
Although estimated associations between ChEI and
memantine use and clinical end points are independent
of patient characteristics that we controlled for in the
models, unobserved characteristics that may differ be-
tween groups may remain and may lead to possible biases
in our results. It is possible that patients who took these
drugs have naturally slower disease progression and their
milder disease course was attributed to drug treatment. As
in all observational studies, we cannot rule out the possi-
bility of effects influencing observed relationships be-
tween treatment and outcomes. It is possible that from
frequent, consistent contact with AD center staff, medical
management of our patients, particularly those who were
treated actively with medications, were better than those
without such access or who were untreated, and may
have biased our results.
Several studies that examined the effects of ChEI 1
memantine combination therapy reported additional benefi-
cial effects of combination therapy in slowed cognitive
and functional decline and delayed nursing home place-
ment [17,19]. In this study, the vast majority of patients
C.W. Zhu et al. / Alzheimer’s & Dementia 9 (2013) 733–740 739who used memantine used it in combination with ChEIs,
with memantine monotherapy reported in only 20 visits
from 14 patients. Therefore, we could not distinguish the
effects of memantine monotherapy vs ChEI 1 memantine
combination therapy. However, the statistically significant
effects of both ChEI and memantine suggest beneficial
effect of ChEI 1 memantine combination therapy in
delaying mortality.
Our ability to estimate duration of medication use was
limited by our data collection method. At each visit, patients
were asked about medication use in the previous 6 months;
however, follow-up was performed annually. Therefore,
medication use was known for half the interval between
visits. This loss of information adds noise to estimation
models. However, unless there were systematic biases in
medication use or discontinuation at 6-month intervals that
were not captured in the data, this loss of information should
not bias our estimation results.
There are several important strengths of our study. First,
there is the large number of well-characterized AD patients
who were monitored prospectively from early disease stages
and examined by the same measures, in the same memory
disorders units, and by the same group of clinicians over
multiple years with good follow-up rates. In contrast to
AD clinical trial and open-label extension studies that typi-
cally include data of, at most, 1 or 2 years, the duration of our
study is substantially longer. Second, our study avoids the
limitations of most clinical trials, which often have stringent
inclusion and exclusion criteria. The sample of patients in-
cluded in this study and results obtained from these patients
therefore reflect more real-world clinical practice. Third,
this study addresses several methodological issues in longi-
tudinal analyses. Because data on clinical outcomes are
often collected at discrete-time intervals (eg, annually), the
commonly used continuous-time methods (eg, Cox models)
are limited. We used the more appropriate discrete-time sur-
vival models, included both time-invariant and time-variant
covariates, and relaxed the often violated proportional haz-
ards assumption when appropriate [33,34,38]. Therefore,
our results go beyond findings from short-term clinical trials
and provide evidence of the effects of ChEIs and memantine
that is fuller and more nuanced, and has real-world clinical
relevance in the treatment of patients with AD.Acknowledgments
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1. Systematic review: Randomized, controlled trials
that examine the effects of cholinesterase inhibitors
and memantine on patient outcomes over long pe-
riods of time are difficult to conduct, and observa-
tional studies are limited with mixed results.
2. Interpretation: Our results extend beyond the context
of controlled trials and open-label extension studies;
our sample has less stringent inclusion/exclusion cri-
teria and is more current, with a substantially longer
study duration. Our methodology allows a more nu-
anced analysis so results have more real-world rele-
vance in the treatment of patients with Alzheimer’s
disease.
3. Future discussions: Future directions include consid-
ering instrumental variables or propensity score ap-
proaches to address some study limitations, such as
the possible that patients who took cholinesterase in-
hibitors and memantine have naturally slower dis-
ease progression, and their milder disease course
was attributed to drug treatment, or the possibility
of other variables influencing observed relationships
between treatment and outcomes. Wewill extend our
study from our current clinical sample to community
samples.
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